Literature DB >> 2224143

Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state.

W Emminger1, W Emminger-Schmidmeier, C Peters, M Susani, R Hawliczek, P Höcker, H Gadner.   

Abstract

A 20 years old man with peripheral primitive neuroectodermal tumor involving the bone marrow received 12 Gy fractionated total body irradiation, 140 mg/m2 melphalan, 1800 mg/m2 etoposide, and 1500 mg/m2 carboplatin for consolidation of first remission. Thereafter, 250 micrograms/m2/day recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) (Behring Werke) were administered as continuous infusion 4 days after infusion of autologous bone marrow and peripheral stem cells to accelerate granulocyte reconstitution for control of a continued febrile state. The clinical picture of capillary leak syndrome developed with weight gain, pleural effusions and peripheral edema. The patient's condition stabilized after discontinuation of rh GM-CSF. Eight days later he died of invasive aspergillosis. The clinical course of our patient suggests a potentially fatal toxic effect of rh GM-CSF, even in low dose, in the setting of septicemia or fungemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224143     DOI: 10.1007/bf01744134

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  13 in total

1.  Modulation of functions of granulocytes by recombinant human GM-CSF and possible complications of GM-CSF therapy.

Authors:  M Klausmann; K H Pflüger; D Krumwieh; F R Seiler; K Havemann
Journal:  Leukemia       Date:  1988-12       Impact factor: 11.528

2.  Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.

Authors:  M A Socinski; S A Cannistra; R Sullivan; A Elias; K Antman; L Schnipper; J D Griffin
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

3.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

5.  Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor.

Authors:  S D Sisson; C A Dinarello
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  S J Brandt; W P Peters; S K Atwater; J Kurtzberg; M J Borowitz; R B Jones; E J Shpall; R C Bast; C J Gilbert; D H Oette
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

7.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.

Authors:  S Vadhan-Raj; M Keating; A LeMaistre; W N Hittelman; K McCredie; J M Trujillo; H E Broxmeyer; C Henney; J U Gutterman
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

8.  Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions.

Authors:  D G Wright; K J Robichaud; P A Pizzo; A B Deisseroth
Journal:  N Engl J Med       Date:  1981-05-14       Impact factor: 91.245

9.  In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.

Authors:  B R Blazar; J H Kersey; P B McGlave; D A Vallera; L C Lasky; R J Haake; B Bostrom; D R Weisdorf; C Epstein; N K Ramsay
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

10.  Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.

Authors:  A Ganser; B Völkers; J Greher; O G Ottmann; F Walther; R Becher; L Bergmann; G Schulz; D Hoelzer
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

View more
  9 in total

1.  Treatment of neutropenia in Felty's syndrome with granulocyte-macrophage colony-stimulating factor--hematological response accompanied by pulmonary complications with lethal outcome.

Authors:  A R Gari-Bai; C Rochlitz; M Riewald; J Oertel; D Huhn
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

2.  GM-CSF therapy and capillary-leak syndrome.

Authors:  M Arning; K O Kliche; W Schneider
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

Review 3.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 4.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

5.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

6.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

7.  Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.

Authors:  K Eguchi; J Kabe; S Kudo; K Mano; H Morinari; K Nakada; K Noda; Y Saito; T Tanaka; T Uzawa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.

Authors:  C B Siegall; D Liggitt; D Chace; M A Tepper; H P Fell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 9.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.